CO6541628A2 - Terapia combinada para enfermedad pulmonar obstructiva crónica (epoc) - Google Patents
Terapia combinada para enfermedad pulmonar obstructiva crónica (epoc)Info
- Publication number
- CO6541628A2 CO6541628A2 CO12092198A CO12092198A CO6541628A2 CO 6541628 A2 CO6541628 A2 CO 6541628A2 CO 12092198 A CO12092198 A CO 12092198A CO 12092198 A CO12092198 A CO 12092198A CO 6541628 A2 CO6541628 A2 CO 6541628A2
- Authority
- CO
- Colombia
- Prior art keywords
- copd
- pulmonary disease
- chronic obstructive
- obstructive pulmonary
- combined therapy
- Prior art date
Links
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 title 1
- 238000009472 formulation Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 abstract 2
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 abstract 2
- 229960002848 formoterol Drugs 0.000 abstract 2
- 229960002462 glycopyrronium bromide Drugs 0.000 abstract 2
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 abstract 1
- 239000000443 aerosol Substances 0.000 abstract 1
- 229950000210 beclometasone dipropionate Drugs 0.000 abstract 1
- 239000006184 cosolvent Substances 0.000 abstract 1
- 229940071648 metered dose inhaler Drugs 0.000 abstract 1
- 150000007522 mineralic acids Chemical class 0.000 abstract 1
- 239000003380 propellant Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/124—Aerosols; Foams characterised by the propellant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
- B65B3/04—Methods of, or means for, filling the material into the containers or receptacles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B31/00—Packaging articles or materials under special atmospheric or gaseous conditions; Adding propellants to aerosol containers
- B65B31/003—Adding propellants in fluid form to aerosol containers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B7/00—Closing containers or receptacles after filling
- B65B7/16—Closing semi-rigid or rigid containers or receptacles not deformed by, or not taking-up shape of, contents, e.g. boxes or cartons
- B65B7/28—Closing semi-rigid or rigid containers or receptacles not deformed by, or not taking-up shape of, contents, e.g. boxes or cartons by applying separate preformed closures, e.g. lids, covers
- B65B7/2842—Securing closures on containers
- B65B7/285—Securing closures on containers by deformation of the closure
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Mechanical Engineering (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- External Artificial Organs (AREA)
Abstract
La invención se relaciona con una formulación en aerosol que es apropiada para administrar a pacientes de EPOC por medio de un inhalador presurizado de dosis medida (pMDl), que comprende bromuro de glicopirronio en combinación con formoterol. La formulación comprende además un propelente de HFA, un cosolvente, y una cantidad de ácido inorgánico que es suficiente para estabilizar tanto el componente de bromuro de glicopirronio como el de formoterol. Opcionalmente la formulación comprende además dipropionato de beclometasona.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09180671 | 2009-12-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6541628A2 true CO6541628A2 (es) | 2012-10-16 |
Family
ID=42107420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO12092198A CO6541628A2 (es) | 2009-12-23 | 2012-06-01 | Terapia combinada para enfermedad pulmonar obstructiva crónica (epoc) |
Country Status (40)
| Country | Link |
|---|---|
| US (3) | US20110150782A1 (es) |
| EP (1) | EP2515855B3 (es) |
| JP (2) | JP5914354B2 (es) |
| KR (2) | KR20170040392A (es) |
| CN (2) | CN102665679B (es) |
| AR (2) | AR079726A1 (es) |
| AU (3) | AU2010334859A1 (es) |
| BR (1) | BR112012015337B8 (es) |
| CA (1) | CA2785321C (es) |
| CL (1) | CL2012001705A1 (es) |
| CO (1) | CO6541628A2 (es) |
| CY (2) | CY1115116T1 (es) |
| DK (1) | DK2515855T6 (es) |
| EA (2) | EA021917B1 (es) |
| ES (1) | ES2468840T7 (es) |
| FI (2) | FIC20170064I1 (es) |
| GE (1) | GEP20156311B (es) |
| HR (1) | HRP20140582T4 (es) |
| HU (1) | HUS1800001I1 (es) |
| IL (1) | IL260932B (es) |
| LT (1) | LTC2515855I2 (es) |
| LU (1) | LUC00060I2 (es) |
| MA (1) | MA33823B1 (es) |
| MX (1) | MX2012006878A (es) |
| MY (1) | MY156949A (es) |
| NL (1) | NL300923I2 (es) |
| NO (1) | NO2018001I2 (es) |
| NZ (1) | NZ600790A (es) |
| PE (2) | PE20160853A1 (es) |
| PH (1) | PH12012501066A1 (es) |
| PL (1) | PL2515855T6 (es) |
| PT (1) | PT2515855E (es) |
| RS (1) | RS53391B2 (es) |
| SG (1) | SG181868A1 (es) |
| SI (1) | SI2515855T1 (es) |
| TN (1) | TN2012000269A1 (es) |
| TW (1) | TWI495468B (es) |
| UA (1) | UA113832C2 (es) |
| WO (1) | WO2011076843A2 (es) |
| ZA (1) | ZA201204615B (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY156950A (en) * | 2009-12-23 | 2016-04-15 | Chiesi Farma Spa | Aerosol formulation for copd |
| EP2515855B3 (en) * | 2009-12-23 | 2023-05-03 | Chiesi Farmaceutici S.p.A. | Combination therapy for COPD |
| ES2468835T3 (es) * | 2009-12-23 | 2014-06-17 | Chiesi Farmaceutici S.P.A. | Terapia combinada para EPOC |
| AU2012216890A1 (en) * | 2011-02-17 | 2013-09-05 | Cipla Limited | Combination of glycopyrrolate and a beta2 -agonist |
| KR102017915B1 (ko) | 2011-10-11 | 2019-09-03 | 키에시 파르마슈티시 엣스. 피. 에이. | 지방산으로 코팅된 베타-작용제의 결정미세입자 |
| MX2015003731A (es) * | 2012-10-23 | 2015-06-15 | Cipla Ltd | Composicion farmaceutica. |
| PT3019153T (pt) | 2013-07-11 | 2018-12-04 | Chiesi Farm Spa | Formulação de pó seco que compreende um anticolinérgico, um corticosteroide e um beta-adrenérgico para administração por inalação |
| LT3089735T (lt) * | 2013-12-30 | 2018-09-10 | Chiesi Farmaceutici S.P.A. | Glikopironio bromido ir formoterolio derinio stabili suslėgta aerozolinė tirpalo kompozicija |
| HUE039359T2 (hu) * | 2013-12-30 | 2018-12-28 | Chiesi Farm Spa | Glikopirrónium-bromid és formoterol kombináció stabil, túlnyomásos aeroszol oldat készítménye |
| US11039621B2 (en) | 2014-02-19 | 2021-06-22 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
| US9622483B2 (en) | 2014-02-19 | 2017-04-18 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
| US11039620B2 (en) | 2014-02-19 | 2021-06-22 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
| US9554992B2 (en) * | 2014-06-09 | 2017-01-31 | Chiesi Farmaceutici S.P.A. | Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic |
| GB201416909D0 (en) * | 2014-09-25 | 2014-11-12 | Prosonix Ltd | Method of forming concentrated solution |
| US20160310410A1 (en) | 2015-04-24 | 2016-10-27 | Glenmark Specialty S.A. | Pharmaceutical compositions comprising arformoterol and glycopyrronium |
| PT3620176T (pt) * | 2015-11-16 | 2021-09-28 | Chiesi Farm Spa | Processo para preparar uma formulação de pó seco que compreende um anticolinérgico, um corticosteroide e um beta-adrenérgico |
| GB2545025A (en) * | 2015-12-04 | 2017-06-07 | Mexichem Fluor Sa De Cv | Pharmaceutical composition |
| EP3436115B1 (en) | 2016-03-31 | 2021-07-28 | Chiesi Farmaceutici S.p.A. | Aerosol inhalation device |
| US10098837B2 (en) | 2016-07-28 | 2018-10-16 | Chiesi Farmaceutici S.P.A. | Combination therapy for COPD |
| AU2017328910B2 (en) | 2016-09-19 | 2020-04-09 | Mexichem Fluor S.A. De C.V. | Pharmaceutical composition |
| EP3515439B1 (en) * | 2016-09-19 | 2021-12-15 | Mexichem Fluor S.A. de C.V. | Pharmaceutical composition comprising tiotropium bromide |
| MX387723B (es) | 2016-09-19 | 2025-03-18 | Mexichem Fluor Sa De Cv | Composición farmacéutica que comprende bromuro de glicopirronio, propionato de fluticasona y 1,1-difluoroetano. |
| MA48620A (fr) * | 2017-05-11 | 2021-04-28 | Chiesi Farm Spa | Procédé de préparation d'une formulation de poudre sèche contenant un anticholinergique, un corticostéroïde et un bêta-adrénergique |
| EP3621590B1 (en) | 2017-05-11 | 2021-09-01 | Chiesi Farmaceutici S.p.A. | A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic |
| EA202092976A1 (ru) * | 2018-06-04 | 2021-03-16 | Люпин Инк. | Устойчивые фармацевтические композиции для дозированных ингаляторов под давлением |
| WO2021110239A1 (en) * | 2019-12-02 | 2021-06-10 | Chiesi Farmaceutici S.P.A. | Stainles steel can for pressurised metered dose inhalers |
| FI4188327T3 (fi) | 2020-07-31 | 2025-07-25 | Chemo Res S L | Yhdistelmähoito inhalaatioannosteluun |
| AU2021356146A1 (en) | 2020-10-09 | 2023-05-04 | Chiesi Farmaceutici S.P.A. | A pharmaceutical formulation for pressurised metered dose inhaler |
| EP4531920A1 (en) | 2022-05-27 | 2025-04-09 | Chiesi Farmaceutici S.p.A. | A pharmaceutical formulation for pressurised metered dose inhaler |
| AU2023275947A1 (en) | 2022-05-27 | 2025-01-16 | Chiesi Farmaceutici S.P.A. | A pharmaceutical formulation for pressurised metered dose inhaler |
| WO2023227782A1 (en) | 2022-05-27 | 2023-11-30 | Chiesi Farmaceutici S.P.A. | A pharmaceutical formulation for pressurised metered dose inhaler |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2956062A (en) | 1959-02-26 | 1960-10-11 | Robins Co Inc A H | Esters of amino alcohols |
| DK0673240T3 (da) * | 1992-12-09 | 1999-10-11 | Boehringer Ingelheim Pharma | Stabiliserede medicinske aerosolopløsningsformuleringer |
| DE59911149D1 (de) | 1998-07-24 | 2004-12-30 | Jago Res Ag Muttenz | Medizinische aerosolformulierungen |
| AU749697B2 (en) | 1998-08-04 | 2002-07-04 | Jagotec Ag | Medicinal aerosol formulations |
| US20060171899A1 (en) * | 1998-12-10 | 2006-08-03 | Akwete Adjei | Water-stabilized aerosol formulation system and method of making |
| IT1317720B1 (it) | 2000-01-07 | 2003-07-15 | Chiesi Farma Spa | Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani. |
| GB0008660D0 (en) | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
| US20060257324A1 (en) * | 2000-05-22 | 2006-11-16 | Chiesi Farmaceutici S.P.A. | Pharmaceutical solution formulations for pressurised metered dose inhalers |
| BR0015884A (pt) * | 2000-05-22 | 2003-07-08 | Chiesi Farma Spa | Formulações de soluções farmacêuticas estáveis para inaladores de dose medida pressurizados |
| DE50211045D1 (de) | 2001-03-30 | 2007-11-22 | Jagotec Ag | Medizinische aerosolformulierungen |
| US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
| EP1321159A1 (en) | 2001-12-21 | 2003-06-25 | CHIESI FARMACEUTICI S.p.A. | Pressurized metered dose inhaler (pMDI) actuators with laser drilled orifices |
| HUE044926T2 (hu) | 2002-03-01 | 2019-11-28 | Chiesi Farm Spa | Szuperfinom formoterolkészítmény |
| AU2003303029A1 (en) | 2002-12-16 | 2004-07-09 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tiotropium containing hfc solution formulations |
| AR041873A1 (es) * | 2003-10-30 | 2005-06-01 | Pablo Cassara Srl Lab | Una formulacion farmaceutica en aerosol adecuada para la inhalacion oral o nasal que contienen glucocorticoides en solucion estable al almacenamiento; un metodo para estabilzar formulaciones y uso de un agente estabilizante |
| AU2005210085B2 (en) | 2004-02-06 | 2010-06-24 | Meda Pharma Gmbh & Co. Kg | The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and COPD |
| RU2438660C2 (ru) * | 2004-02-06 | 2012-01-10 | Меда Фарма Гмбх Унд Ко. Кг | Комбинация и фармацевтический препарат для лечения воспалительных и обструктивных заболеваний дыхательных путей |
| GB0410399D0 (en) | 2004-05-10 | 2004-06-16 | Arakis Ltd | The treatment of respiratory disease |
| GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
| EP1616567A1 (en) | 2004-07-16 | 2006-01-18 | Boehringer Ingelheim Pharma GmbH & Co.KG | Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts |
| GB0505545D0 (en) | 2005-03-17 | 2005-04-27 | Glaxo Group Ltd | Inhalation devices |
| CA2603433A1 (en) | 2005-03-30 | 2006-10-05 | Schering Corporation | Medicaments and methods combining an anticholinergic, a corticosteroid, and a long acting beta agonist |
| GB0523653D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| AU2006276343B2 (en) | 2005-08-01 | 2009-10-08 | Astrazeneca Ab | Inhaler valve |
| GB0523655D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| GB0523656D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| GB0523654D0 (en) * | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| PL1971369T3 (pl) * | 2005-12-21 | 2010-01-29 | Meda Pharma Gmbh & Co Kg | Połączenie R,R-glikopirolanu, rolipramu i budesonidu dla potrzeb leczenia chorób zapalnych |
| GB0613161D0 (en) | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
| EP1894568A1 (en) * | 2006-08-31 | 2008-03-05 | Novartis AG | Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases |
| ES2969237T3 (es) | 2007-10-18 | 2024-05-17 | Rose U Llc | Formulaciones tópicas de glicopirrolato y una toallita que contiene las mismas |
| EP2440196A4 (en) * | 2009-06-09 | 2013-01-02 | Elevation Pharmaceuticals Inc | TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY ADMINISTRATION OF BETA 2 NEBULIZED AGONIST OR A COMBINATION OF BETA 2 NEBULIZED AGONIST AND ANTICHOLINERGIC |
| MY156950A (en) * | 2009-12-23 | 2016-04-15 | Chiesi Farma Spa | Aerosol formulation for copd |
| KR20120106753A (ko) | 2009-12-23 | 2012-09-26 | 키에시 파르마슈티시 엣스. 피. 에이. | Ｃｏｐｄ용 에어로졸 제제 |
| EP2515855B3 (en) * | 2009-12-23 | 2023-05-03 | Chiesi Farmaceutici S.p.A. | Combination therapy for COPD |
| ES2468835T3 (es) | 2009-12-23 | 2014-06-17 | Chiesi Farmaceutici S.P.A. | Terapia combinada para EPOC |
| PT3019153T (pt) * | 2013-07-11 | 2018-12-04 | Chiesi Farm Spa | Formulação de pó seco que compreende um anticolinérgico, um corticosteroide e um beta-adrenérgico para administração por inalação |
| HUE039359T2 (hu) * | 2013-12-30 | 2018-12-28 | Chiesi Farm Spa | Glikopirrónium-bromid és formoterol kombináció stabil, túlnyomásos aeroszol oldat készítménye |
| LT3089735T (lt) * | 2013-12-30 | 2018-09-10 | Chiesi Farmaceutici S.P.A. | Glikopironio bromido ir formoterolio derinio stabili suslėgta aerozolinė tirpalo kompozicija |
| US9554992B2 (en) * | 2014-06-09 | 2017-01-31 | Chiesi Farmaceutici S.P.A. | Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic |
| US10098837B2 (en) * | 2016-07-28 | 2018-10-16 | Chiesi Farmaceutici S.P.A. | Combination therapy for COPD |
-
2010
- 2010-12-22 EP EP10799030.1A patent/EP2515855B3/en active Active
- 2010-12-22 DK DK10799030.1T patent/DK2515855T6/da active
- 2010-12-22 PE PE2016000787A patent/PE20160853A1/es unknown
- 2010-12-22 MX MX2012006878A patent/MX2012006878A/es active IP Right Grant
- 2010-12-22 MY MYPI2012002844A patent/MY156949A/en unknown
- 2010-12-22 EA EA201290375A patent/EA021917B1/ru active Protection Beyond IP Right Term
- 2010-12-22 AU AU2010334859A patent/AU2010334859A1/en not_active Abandoned
- 2010-12-22 HR HRP20140582TT patent/HRP20140582T4/hr unknown
- 2010-12-22 KR KR1020177009412A patent/KR20170040392A/ko not_active Ceased
- 2010-12-22 PH PH1/2012/501066A patent/PH12012501066A1/en unknown
- 2010-12-22 AR ARP100104922A patent/AR079726A1/es not_active Application Discontinuation
- 2010-12-22 CN CN201080058048.8A patent/CN102665679B/zh active Active
- 2010-12-22 PT PT107990301T patent/PT2515855E/pt unknown
- 2010-12-22 EA EA201590179A patent/EA027778B1/ru active Protection Beyond IP Right Term
- 2010-12-22 PE PE2012000865A patent/PE20121396A1/es not_active Application Discontinuation
- 2010-12-22 UA UAA201207626A patent/UA113832C2/uk unknown
- 2010-12-22 CA CA2785321A patent/CA2785321C/en active Active
- 2010-12-22 NZ NZ600790A patent/NZ600790A/en unknown
- 2010-12-22 CN CN201410289445.6A patent/CN104055765B/zh active Active
- 2010-12-22 SG SG2012046157A patent/SG181868A1/en unknown
- 2010-12-22 TW TW099145166A patent/TWI495468B/zh active
- 2010-12-22 KR KR1020127015996A patent/KR101757951B1/ko active Active
- 2010-12-22 JP JP2012545323A patent/JP5914354B2/ja active Active
- 2010-12-22 GE GEAP201012756A patent/GEP20156311B/en unknown
- 2010-12-22 ES ES10799030T patent/ES2468840T7/es active Active
- 2010-12-22 SI SI201030654T patent/SI2515855T1/sl unknown
- 2010-12-22 RS RS20140338A patent/RS53391B2/sr unknown
- 2010-12-22 WO PCT/EP2010/070479 patent/WO2011076843A2/en not_active Ceased
- 2010-12-22 PL PL10799030.1T patent/PL2515855T6/pl unknown
- 2010-12-22 BR BR112012015337A patent/BR112012015337B8/pt active IP Right Grant
- 2010-12-23 US US12/977,159 patent/US20110150782A1/en not_active Abandoned
-
2012
- 2012-05-29 TN TNP2012000269A patent/TN2012000269A1/en unknown
- 2012-06-01 CO CO12092198A patent/CO6541628A2/es unknown
- 2012-06-14 MA MA34966A patent/MA33823B1/fr unknown
- 2012-06-21 ZA ZA2012/04615A patent/ZA201204615B/en unknown
- 2012-06-21 CL CL2012001705A patent/CL2012001705A1/es unknown
-
2014
- 2014-05-29 CY CY20141100382T patent/CY1115116T1/el unknown
-
2015
- 2015-07-29 US US14/812,190 patent/US10159645B2/en active Active
-
2016
- 2016-04-04 JP JP2016075136A patent/JP6283388B2/ja active Active
- 2016-09-27 AU AU2016234895A patent/AU2016234895B2/en active Active
-
2017
- 2017-12-22 CY CY2017047C patent/CY2017047I1/el unknown
- 2017-12-29 FI FIC20170064C patent/FIC20170064I1/fi unknown
- 2017-12-29 FI FIEP10799030.1T patent/FI2515855T6/fi active
-
2018
- 2018-01-05 HU HUS1800001C patent/HUS1800001I1/hu unknown
- 2018-01-10 NO NO2018001C patent/NO2018001I2/no unknown
- 2018-01-10 LU LU00060C patent/LUC00060I2/fr unknown
- 2018-01-11 LT LTPA2018001C patent/LTC2515855I2/lt unknown
- 2018-01-12 NL NL300923C patent/NL300923I2/en unknown
- 2018-04-30 AU AU2018202998A patent/AU2018202998A1/en not_active Abandoned
- 2018-08-01 IL IL260932A patent/IL260932B/en active IP Right Grant
- 2018-10-16 US US16/161,427 patent/US11389401B2/en active Active
-
2019
- 2019-08-02 AR ARP190102199A patent/AR115897A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6541628A2 (es) | Terapia combinada para enfermedad pulmonar obstructiva crónica (epoc) | |
| WO2011076841A3 (en) | Combination therapy for copd | |
| CL2022002235A1 (es) | Inhaladores dosificadores presurizados que comprenden una formulación farmacéutica amortiguada | |
| AR038641A1 (es) | Formulacion superfina de formoterol | |
| AR101593A2 (es) | Formulación superfina de formoterol | |
| ME02342B (me) | Farmaceutske formulacije rastvora za izmjerene doze inhalatora pod pritiskom | |
| NI201400139A (es) | Nueva forma de dosificación y formulación de abediterol | |
| UY31686A1 (es) | Nueva dosificacion y formulacion | |
| BR112014008601A2 (pt) | fabricação de tubos de aerossol para insumos medicinais | |
| UY31687A1 (es) | Nueva dosificacion y formulacion | |
| TR201000680A2 (tr) | Tiotropyum, formoterol ve budesonid içeren farmasötik bileşimler | |
| EA201201397A1 (ru) | Ингалятор, содержащий расслаиваемую блистерную упаковку | |
| CO2022012207A2 (es) | Inhaladores de dosis medida presurizada que comprenden una formulación farmacéutica amortiguada | |
| MX2020003436A (es) | Inhalador de polvo seco y metodo de uso. | |
| CL2023000998A1 (es) | Formulación farmacéutica para inhalador presurizado de dosis medidas | |
| AR123674A2 (es) | Composición farmacéutica en aerosol de formoterol y dipropionato de beclometasona | |
| EA201201394A1 (ru) | Ингалятор для доставки лекарственного средства в виде сухого порошка | |
| AR089101A1 (es) | Formulacion nasal | |
| AR094287A1 (es) | Metodos y composiciones para administracion de oxibutinina | |
| BR102012008322B8 (pt) | formulações medicinais em aerossol que não debilitam a camada de ozônio e com baixo efeito estufa | |
| TH127043A (th) | ผลิตภัณฑ์รวมสำหรับบำบัด copd |